29
May 20
COVID-19 emergency and processing of health data for scientific research purposes
The health emergency due to the spread of COVID-19 has made the need to correctly manage the processing of health data for scientific research purposes even more topical.
29
May 20
Italy: Garante's crackdown on patient health data protection
The Italian data protection authority (‘Garante’) announced, on 6 March 2020, that it had reached an agreement with Consip S.p.a. regarding modifications rules regarding calls for tenders concerning the purchase of medical equipment and devices, aimed at making the same compliant with data protection legislation.
9
Apr 20
COVID-19 emergency: increasingly dematerialized prescriptions
In order to reduce the spread of Covid-19, on March 19 the Head of the Civil Protection Department adopted an ordinance (“Ocdpc 651/2020” or “Ordinance“) allowing a citizen to receive from his/her physician an electronic prescription number (numero di ricetta elettronica – “NRE“), which is necessary to get a prescription drug from a pharmacy, without going to the doctor’s office.
11
Feb 20
EDPS: clarification on data protection and scientific research
On January 6, 2020, the European Data Protection Supervisor (EDPS) issued a preliminary opinion on data protection and scientific research, in which it provided clarification on the application of data protection rules established by the General Data Protection Regulation (GDPR) and Regulation No. 2018/1725 with regard to scientific research.
22
Oct 19
Artificial Intelligence in healthcare between opportunities and new challenges
Artificial Intelligence (AI) is becoming an increasingly important protagonist in the healthcare sector, undoubtedly gaining its place among tomorrow’s main challenges.
4
Apr 19
A joint HMA and EMA taskforce analyzes the use of big data for the evaluation and monitoring of medicines
The Joint Big Data taskforce (“Taskforce”) between the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) was formed to describe the big data landscape from a regulatory perspective in order to ensure that the EU regulatory system has the capability and capacity to guide, analyze and interpret this data. Its work aims to facilitate the use of such data for the process of evaluation and monitoring of medicines by the regulatory authorities, analyzing the risk-benefit of medicinal products during their lifetime.
